BR96 sFv PE40
Alternative Names: BMS 191352; BR96 SCIT; SGN 10Latest Information Update: 15 Dec 2023
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Seattle Genetics
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer